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ABSTRACT: 
Background: The number of patients with type 2 diabetes mellitus (T2DM) and chronic kidney 
disease (DKD) varies considerably between countries. Next to differences in genetic as well as 
life style risk factors varying practices in medical care delivery might cause this diversity. 
Method: The PROVALID study recruited 4.000 patients with T2DM at the primary level of 
healthcare in 5 European countries (Austria, Hungary, The Netherlands, Poland and Scotland). 
Baseline data were used to describe patient characteristics and compare the adherence to ADA 
and KDIGO guidelines with respect to metabolic and blood pressure control, use of RAS 
blocking agents, statins and ASA between the countries. 
Results: 34.8% of the population had evidence of DKD. The median HbA1c level of the cohort 
was 6.8% (ranging from 6.5 in Poland to 7.0% in Scotland). Mean blood pressure was 136/79 
(±17/10) and significantly higher in subjects with elevated albuminuria. These individuals also 
were more often treated with RAS blocking agents (74.1 vs 84.6%), whereas the use of statins 
was driven by cardiovascular comorbidity. ASA was used in only 28.9% subjects. Despite 
similar cardiovascular comorbidities and renal function the use of RAS blocking agents varied 
significantly between the countries from 66.7-87.4%. An even higher variability was observed 
for patients > 40 years of age using statins (39.8-82.7%) and administration of ASA in patients 
older than 50 years (5.2-43.8%). 
Conclusions: Our study shows that medical practise in T2DM patients with and without renal 
disease is different in European countries. Longitudinal follow up will reveal if this diversity 
affects clinical endpoints.    
Keywords: 
Diabetes mellitus; diabetic kidney disease; ADA guideline adherence; KDIGO guideline 
adherence;   
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BACKGROUND 
The Global Burden of Disease Study ranked chronic kidney disease (CKD) 19th on the list of 
all causes of mortality [1]  and the age standardized death rate due to renal failure increased 
from 11.6 to 15.8/100.000 between 1990 and 2013. Diabetes mellitus associated CKD (DKD) 
is a major contributor and the number of diabetic patients with end stage renal disease (ESRD) 
in Europe is expected to rise annually by 3.2% at least until the year 2025 [2]. Next to issues 
directly related to renal replacement therapy (RRT), comorbidities (like premature 
cardiovascular events, increased incidence of fractures, cognitive impairment, and anaemia) 
make DKD an important global health, but also socio-economical problem [3, 4]. 
In order to support clinical decision making and health care policy planning it is important to 
understand the epidemiology of CKD and identify factors associated with its incidence and 
progression, ideally not only in, but also outside the setting of randomized, controlled trials. 
Kramer at al. [5] analysed the 2013 EDTA-ERA registry data on incident patients to RRT. On 
average DKD was listed as the cause of ESRD in 24% (26 pmp), but interestingly the 
differences between countries were remarkable (from 6 in the Ukraine and 12 pmp in Iceland 
to 58 and 70 pmp in Greece and Portugal respectively). Regional variability was observed also 
in non-dialysis dependent CKD in Europe [6], the United States [7] and China [8]. Next to 
heterogeneities in study design, inclusion and/or exclusion criteria or laboratory methodology 
used for creatinine measurement [9]  genetic background driven disease susceptibility as well 
as dietary habits can affect serum creatinine values and/or incidence or progression of the 
disease. Regional differences in risk factors like smoking, physical activity, socioeconomic 
status and birth weight also have to be considered. As far as initiation of renal replacement 
therapy is concerned, patterns of referral to dialysis and/or transplantation may vary and finally 
local health care policies and/or clinical practise pattern (e.g metabolic or blood pressure 
control) might also influence CKD/DKD incidence, prevalence and progression.  
In order to assess the latter we analysed baseline data from the PROVALID study, a prospective 
cohort study that recruited subjects with T2DM at the primary level of healthcare in Austria, 
Hungary, Poland, Scotland and The Netherlands.  
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The aim of our study was to describe whether the presence or absence of renal disease as defined 
by the KDIGO stages [10] affects major aspects of treatment in the total population and in the 
different participating countries. As a measure we used the adherence pattern to ADA and 
KDIGO treatment guideline recommendations for metabolic, blood pressure and LDL 
cholesterol control as well as administration of aspirin [11–13].  
METHODS 
Study design: 
A detailed description of the PROVALID (PROspective cohort-study in patients with T2DM 
for VALIDation of biomarkers) study is presented elsewhere [14]. In summary it is a 
prospective cohort study of 4.000 individuals with incident or prevalent T2DM (defined either 
as treatment with hypoglycaemic drugs or according to ADA guidelines). Subjects older than 
18 years were recruited at the primary level of healthcare in five European countries (629 
patients in Austria, 1420 in Hungary, 903 in The Netherlands, 537 in Poland and 511 in 
Scotland) and only those with active malignancy (defined as those currently receiving 
chemotherapy) or who declined to participate were excluded. The current paper uses individual 
patient data obtained at the time of recruitment into the study (2011 to 2015). According to the 
KDIGO classification system (10) DKD was considered absent in subjects with stages G1 and 
G2 (eGFR >60ml/min/1.73m2) and urinary albumin excretion <30 mg/g creatinine (A1, 
formerly called normoalbuminuria) in a morning spot urine sample.  
Statistical analysis: 
Data are presented as mean±SD, median and interquartile range or percentage as appropriate. 
Data adjusted for age, gender and diabetes duration were calculated by univariate linear 
regression. Comparisons between groups were performed using student’s t-test or One-Way 
Anova followed by Bonferroni post-hoc test, Mann-Whitney-test, Kruskal-Wallis-test or Chi²-
test as appropriate. Missing values were not included for any calculations. All statistics were 
done in IBM SPSS Statistics for Windows, Version 24.0. Armonk, NY: IBM Corp. 
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RESULTS 
The percentage of patients in the different KDIGO stages of DKD (unadjusted as well as 
adjusted for age, gender and diabetes duration) in the total study population as well as the 
national sub-cohorts is given in TABLES 
 
 
Table 1.  
Even though the adjusted as well as unadjusted percentages of KDIGO stages differed 
statistically significantly between the countries, the populations were similar based on clinical 
judgement. About 2/3 of the subjects had normal renal function, 15% had maintained eGFR 
>60 ml/min/1.73m2 but at least moderately increased albuminuria (stages A2 and A3, former 
micro- and macro-albuminuria). In approximately 20% eGFR was decreased <60 
ml/min/1.73m2 (G3 or higher) and in this subgroup 2/3 were in albuminuria stage A1 and only 
8% presented with a urinary albumin excretion >300mg/g creatinine. 
The percentage of patients with cardiovascular comorbidities in the total study population and 
the national sub-cohorts adjusted for age, gender and diabetes duration is presented in  
Table 2. The proportions in parentheses indicate the unadjusted cardiovascular comorbidity 
prevalence. 
 
The prevalence of comorbidities also differed significantly between the countries but in 
absolute terms these variations were small with some exceptions (e.g less age, gender and 
diabetes duration adjusted coronary artery disease in the populations in Poland and Scotland). 
Supplementary table 1 provides information on the prevalence of comorbidities in patients with 
normal renal function and those with CKD. Even though the latter were younger their 
cardiovascular disease burden was significantly higher.  
The KDIGO guidelines recommend a target HbA1c value of 7% to prevent or delay progression 
of microvascular complications of diabetes including DKD. In individuals with comorbidities 
or limited life expectancy the goal should be extended to >7% whereas in those at risk for 
hypoglycaemia HbA1c levels should not be below 7% (10). The ADA (11) recommends an 
HbA1c level around 7% for all T2DM patients except pregnant women but with 
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individualization according to a number of factors. In those with a short disease duration, 
treatment with lifestyle measures or metformin only, a long life expectancy or no significant 
cardiovascular comorbidity the goal can be set for <6.5%. On the contrary those with a risk for 
hypoglycaemia, advanced micro- or macrovascular disease extensive comorbidities or 
longstanding diabetes might aim for <8%.  
Table 3 shows data on the median HbA1c levels and the percentage of patients within specific 
ranges in the total study population and the national sub-cohorts. In all countries except 
Scotland more than 80% of subjects included had an HbA1c of <8% suggesting that in general 
metabolic control was acceptable in the majority of patients. Both, KDIGO (10) and the ADA 
guidelines (12) recommend that blood pressure in patients with T2DM and urinary albumin 
excretion below 30 mg/day should not exceed 140/90 mmHg. In subjects with an elevated 
urinary albumin excretion (A2 and A3) the goal blood pressure is reduced to 130/80. Table 4 
shows the mean blood pressure values for the various groups and the percentage of subjects 
within these recommendations in the total study population and in the various national sub-
cohorts.  
Whereas about 75% of subjects reached goal blood pressure in diabetic patients with normal or 
mildly increased albuminuria (A1), blood pressure was <130/80 mmHg in only 10-20% of 
patients with higher urinary albumin excretion. Interestingly these patients not only reached 
goal blood pressure values less often but even had higher mean systolic blood pressure in all 
countries expect Poland when compared to normoalbuminuric study participants. Worse blood 
pressure control was achieved in patients in stages A2 and A3 when compared to A1 despite 
the fact, that antihypertensive therapy was intensified (see supplementary table 2). Further 
analysis revealed that worse blood pressure control was observed in all countries expect Poland 
in patients at early stages (G1 and G2) of renal disease and at least moderately increased 
albuminuria (A2 and A3) (supplementary table 3) but not in subjects with more advanced renal 
failure.  
Both, KDIGO (10) and the ADA (12) recommend ACE inhibitor or Angiotensin receptor 
blocker (ARB) therapy in patients with T2DM and albuminuria > 30 mg/g creatinine. Table 5 
shows the percentage of subjects treated with these agents in the total study population and in 
the national subpopulations according to their albuminuria status.  
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About three-quarter of all subjects included received RAS blocking therapy (66.7-87.4%). The 
use of the agents was significantly higher in patients with KDIGO stages A2 and A3 in all 
countries expect in Poland. Additionally patients with KDIGO stages G3 or higher were also 
preferentially treated by RAS blockade (with the exception of expect for Poland and The 
Netherlands; supplementary table 4a). A more detailed analysis of RAS blocking therapy 
according to different KDIGO classification groups is provided in supplementary table 4b. RAS 
blocking therapy was more prevalent in subjects in stages A2 or A3 in G 1and 2 stages of the 
disease. The same trend could not be observed in more advanced G stages, if anything the 
frequency of administration was lower in the presence of moderately or severely increased 
albuminuria. Additional analysis of this subgroup showed that normoalbuminuric patients with 
eGFR values below 60 ml/min/1.73m2 had higher mean eGFR but lower blood pressure than 
their albuminuric counterparts (50.8 ml/min/1.73m2, IQR 42.4-55.2 vs 44.0 ml/min/1.73m2, 
IQR 32.8-57.4; p<0.001; 136/77±17/10 vs. 138/79±18/11; p= 0.09/0.01). Additionally the 
serum potassium levels were identical (4.5 mmol/l, IQR 4.2-4.8 vs.  4.5mmol/l IQR 4.1-5.0; 
p=0.277). Thus based on these cross sectional data we cannot explain the lower use of 
ACE/ARB therapy in patients with advanced renal disease and moderately or severely increased 
albuminuria. It could be speculated that some initially albuminuric subjects had regressed to 
normoalbuminuria but stayed on RAS blocking therapy.  
As far as cholesterol lowering therapy is concerned the ADA guidelines recommend that all 
diabetic patients over the age of 40 should receive a statin (12). KDIGO suggests statin therapy 
for all patients with CKD (10). Table 6 shows details on adherence to these guidelines. In Table 
7 the use of aspirin is given, which is recommended for all diabetic patients >50 years of age 
by the ADA (13) and for all subjects with CKD by KDIGO (10). Serum cholesterol levels were 
significantly different between the countries. 3902 subjects were older than 40 years and thus 
generally eligible for statin therapy according to the ADA guidelines. In countries with high 
use of statins the presence of renal disease did not affect statin prescription frequency. However 
in the two countries with less than 50 statin use in general (Austria and Poland), subjects with 
renal disease were more likely to be prescribed statin therapy. 
In general patients on statin therapy were older, more likely to be male and had significantly 
lower cholesterol levels than those not treated. Their cardiovascular comorbidity was much 
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higher leading to the conclusion that prescription of statin therapy was driven rather by 
cardiovascular comorbidity than guideline recommendation. 
Overall ASA use was low in all countries, of the 3560 patients older than 50 years only about 
29 % were treated. However a huge difference between the countries was observed. On average, 
patients with renal disease were more likely to be treated. Similar to statin therapy the 
administration of ASA was mostly driven by the presence of cardiovascular disease and 
especially coronary artery, peripheral or cerebrovascular disease. Interestingly patients with 
advanced heart failure were significantly less likely to receive ASA containing drugs.  
 
DISCUSSION 
In general our study shows that there is room for improvement regarding guideline adherence 
at the primary level of healthcare in patients with T2DM at least in the European countries 
included in PROVALID. Blood pressure control was poor in patients with elevated albuminuria 
with only 15% of all subjects reaching the recommended target values of <130/80 mmHg. Both 
ADA and KDIGO suggest statin therapy in patients with T2DM or CKD without taking care of 
serum cholesterol levels, yet only about 60% of participants received medication. The rate of 
prescription was even lower for ASA (approximately 30%). Our data suggest that contrary to 
guideline recommendations the latter two treatments were rather used because of the presence 
of cardiovascular comorbidities than in a “primary prevention” effort.      
An additional interesting aspect is the large variability of therapeutic practice pattern between 
the countries despite the fact that the populations recruited were quite similar with regard to 
patient history and the prevalence of risk factors and comorbidities. One reason for the observed 
diversity could be that GPs rather follow national guidelines. However the Austrian Society of 
Nephrology has endorsed the KDIGO guidelines and the Austrian Diabetes Association [15]  
issued a statement that also closely follows the ADA/KDIGO suggestions. The situation is 
similar in Scotland [16], Poland (A. Wiecek, personal communication) and Hungary [17, 18]. 
Guidelines in the Netherlands also mostly follow KDIGO and ADA but suggest even lower 
blood pressure goals. However, statin therapy is recommended only in patients with elevated 
serum cholesterol and diuretics should be administered as first line therapy in selected 
circumstances [19]. 
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Available evidence-based guidelines provide targets and performance measures for the 
treatment of T2DM patients but obviously a wide gap separates guidelines-driven 
recommendations from their clinical application, a phenomenon hindering the transfer of 
proven benefits to affected populations. In this regard the results of our study replicate the 
findings of other authors in patients with diabetes and comorbidities like coronary artery or 
cerebrovascular disease. Bohn et al. studied almost 30.000 German and Austrian patients with 
T2DM with respect to secondary prevention after myocardial infarction and stroke [20]. HbA1c 
goal according to national guidelines <7.5 % was achieved in 64.9 % (myocardial infarction, 
MI), and in 61.1 % (stroke) of patients respectively, LDL cholesterol <100 mg/dl was 
documented in 56.2 % (MI), and in 42.2 % (stroke). Target values of blood pressure (<130/80 
mmHg in MI, 120/70-140/90 in stroke) were reached in 67.0 % (MI), and in 89.9 % (stroke). 
Prescription prevalence of inhibitors of platelet aggregation was 50.7 % (MI), and 31.7 % 
(stroke). 57% (MI), and 40.1 % (stroke) used statins. Similar data were reported by Modesti et 
al. in Italy and Renard et al. in Luxemburg [21, 22]. A total of 6187 patients with coronary 
artery disease were investigated in EUROASPIRE IV in 24 European countries 2012-2013. 
46% had no diabetes, 19% were newly diagnosed at enrolment and 35% were known diabetics. 
The optimum use of cardio-protective drugs in these groups was 53, 55 and 60%, respectively. 
A blood pressure target of <140/90 mmHg was achieved in 68, 61, 54% and a LDL-cholesterol 
target of <1.8 mmol/l in 16, 18 and 28%. Despite the fact that, compared with data from 
previous surveys, the use of cardio-protective drugs had increased and more patients were 
achieving the risk factor treatment targets the authors concluded that there is further potential 
to improve the management of patients with diabetes and coronary artery disease [23]. 
Several efforts have been tested for their capacity to improve guideline adherence. In the USA 
Kuo et al. compared care provided to patients with diabetes mellitus by nurse practitioners 
(NPs) and primary care physicians (PCPs) and found no significant difference. NPs and PCPs 
had similar rates of LDL-C testing and nephropathy monitoring, but NPs had lower rates of eye 
examinations and HbA1c testing. NPs were more likely to have consulted cardiologists, 
endocrinologists, and nephrologists. There was no statistically significant difference in adjusted 
Medicare spending between the two groups[24].  
Another approach taken is to use incentive based primary care, a fee for service funding model. 
In British Columbia these incentives, after controlling for patients' age, sex, service needs level, 
  
 
10 
 
 
 
and continuity of care (defined as attachment to a general practice), reduced the net annual 
health care costs for patients with hypertension, chronic obstructive pulmonary disease, and 
congestive heart failure, but not diabetes mellitus[25]. A recent Cochrane Database review 
concluded that the use of financial incentives is growing but the authors put forward that there 
is insufficient evidence to support or not support this trend. Implementation should proceed 
with caution and incentive schemes should be more carefully designed before 
implementation[26]. In line with this Boyd et al. concluded for a group of elderly multi-morbid 
subjects pay for service incentives and the resulting adherence to guidelines lead to undesired 
polypharmacy and inadequate care[27]. In this context it should be mentioned that during the 
recruitment phase of PROVALID GP services in Scotland were financially incentivised to have 
high ACE inhibitor/statin use in patients with T2DM. 
Electronic health records might be an interesting tool to improve guideline adherence. In a study 
by Ancker et al. [28] (183.095 visits with 61.977 patients) condition-specific best-practice alerts 
and order sets were associated with better scores on clinical quality measures capturing 
processes in diabetes, cancer screening, tobacco cessation, and pneumonia vaccination. For 
example, providers above the median in use of tobacco-related alerts had higher performance 
on tobacco cessation intervention metrics, and providers above the median in use of diabetes 
order sets had higher quality on diabetes low density lipoprotein (LDL) testing. However, post 
hoc examination of the results showed that the positive associations were with measures of 
healthcare processes (such as rates of LDL testing), whereas there were no positive associations 
with measures of healthcare outcomes (such as LDL levels) [28]. Similar effects were reported 
by Benkert et al. [29].  
Finally CME efforts might be applied. 53% of 383 physicians completing a questionnaire 
reported using diabetes guidelines routinely. Mean diabetes knowledge score for guideline 
users was significantly higher than non-guideline users. The former were significantly more 
likely to report a good understanding of type 2 diabetes medications, less likely to report their 
unfamiliarity with insulin as an important barrier to early insulin use and with pharmacologic 
options as a barrier to prescribing intensive multifactorial interventions. Associations remained 
significant after adjusting for physician specialty, practice volume and frequency diagnosing or 
treating diabetes patients [30]. 
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CONCLUSION 
In summary our study shows that international society guidelines for patients with T2DM are 
only partially followed at the primary level of healthcare in the European countries included in 
our study. Additionally treatment applied varies widely. It cannot be answered by our cross 
section analysis if this diversity impacts clinical outcomes. Only longitudinal follow up data 
from our cohort will help us to understand if our findings contribute to the reported national 
variability in the incidence of ESRD. 
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TABLES 
 
 
Table 1: Percentage of patients in the different KDIGO stages of DKD 
  total Austria Hungary 
Nether 
lands 
Poland Scotland p-value* 
G1 or G2 and A1 (%) 65.2 64.8 4 (60.3) 62.2 1 (60.2) 64.8 6 (77.5) 68.6  1 (57.8) 68.5 1 (71.6) <0.001 
G1 or G2 and A2 or A3 (%) 15.5 15.6 3 (17.5) 15.1 1 (12.8) 15.8 3 (11.7) 15.3 4;6 (23.1) 16.5 1  (18.8) <0.001 
≥ stage G3 and A1 (%) 12.8 13.1 4 (15.3) 14.9 1 (18.0) 12.9 6 (9.1) 10.8 1 (9.3) 9.6 1 (6.0) <0.001 
≥ stage G3 and A2 or A3 (%) 6.5 6.5 4 (6.9) 7.8 1 (9.1) 6.4 6 (1.8) 5.3 1(9.7) 5.4 1 (3.6) <0.001 
any G and A1 (%) 78.0 77.9 2;4 (75.6) 77.11 (78.2) 77.8  2;6 (86.6) 79.4 1 (67.2) 78.1 3;6 (77.6) <0.001 
any G and A2 or A3 (%) 22.0 22.1 2;4 (24.4) 22.9 1 (21.8) 22.2 2;6  (13.4) 20.6 1 (32.8) 21.9 3;6 (22.4) <0.001 
G1 or G2 (%) 80.7 80.4 4 (77.8) 77.3 1 (73.0) 80.6 6 (89.1) 83.9 2 (81.0) 85.0 3 (90.3) <0.001 
≥ stage G3 (%) 19.3 19.6 4 (22.2) 22.7 1 (27.0) 19.4 6 (10.9) 16.1 1 (19.0) 15.0 1 (9.7) <0.001 
1 significantly different from all countries  
2 significantly different from all countries except Scotland 
3 significantly different from all countries except Poland 
4 significantly different from all countries except the Netherlands 
5 significantly different from all countries except Hungary  
6 significantly different from all countries except Austria 
Percentages are adjusted for age, gender and diabetes duration; unadjusted percentages are given in parenthesis. 
*p values apply for adjusted as well as unadjusted data  
 
 
Table 2: Percentage of patients with cardiovascular comorbidities 
 Total Austria Hungary Netherlands Poland Scotland p-value* 
Heart failure stage III/IV 2.5 2.4 4 (4.3) 3.2 1 (3.3) 2.4 6 (0.0) 2.4 1 (3.4) 1.6 1 (1.0) <0.001 
Coronary artery disease 21.0 21.6 4;5 (19.0) 22.7 6 (21.5)  22.1 6 (18.9)  15.9 1 (27.2) 18.7 1 (19.2) <0.001 
Peripheral artery disease 7.1 6.7 2;4 (8.0) 8.8 1 (8.9) 6.6 6 (1.7) 5.4 1 (9.1) 6.2 6 (7.4) <0.001 
Cerebrovascular disease 6.7 6.8 4 (10.1) 7.7 (7.9) 6.8 6 (1.1) 5.3 (9.1) 5.8 (5.7) <0.001 
1 significantly different from all countries  
2 significantly different from all countries except Scotland 
3 significantly different from all countries except Poland 
4 significantly different from all countries except the Netherlands 
5 significantly different from all countries except Hungary  
6 significantly different from all countries except Austria 
Percentages are adjusted for age, gender and diabetes duration; unadjusted percentages are given in parenthesis. 
*p values apply for adjusted as well as unadjusted data  
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Table 3: Median HbA1c levels and the percentage of patients within specific ranges 
 Total Austria Hungary Netherlands Poland Scotland p-value* 
HbA1c 6.8 (6.2; 7.5) 6.7 (6.2; 7.4) 4;5 6.9 (6.2; 7.7) 4; 6 6.7 (6.4; 7.3) 5;6 6.5 (5.9; 7.2) 1 7 (6.4; 8) 1 <0.001 
<6 % (%) 15.6 13.4 18.0 7.5 27.0 13.3 <0.001 
6-<8 % (%)  69.6 74.5 63.4 84.6 61.6 62.7 <0.001 
8-<10 % (%) 12.3 10.4 15.6 7.4 9.7 17.2 <0.001 
>10 % (%) 2.5 1.7 3.0 0.5 1.7 6.8 <0.001 
 
1 significantly different from all countries  
2 significantly different from all countries except Scotland 
3 significantly different from all countries except Poland 
4 significantly different from all countries except the Netherlands 
5 significantly different from all countries except Hungary  
6 significantly different from all countries except Austria 
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Table 4: Mean blood pressure values and percentage of subjects reaching recommended blood 
pressure goal levels 
 total Austria Hungary Nether 
lands 
Poland Scotland p-value 
Systolic/diastolic blood pressure 
values (mmHg) 
137 / 
80 
±17/10 
140 7 / 
82 7; 9; 10 
±19/10 
134 1 / 
78 8; 11 
±15/9 
138 7 / 
78  8; 10; 
11 
±17/10 
139 7 / 
84 7; 9 
±18/11 
136 7 / 
79 8; 11 
±17/10 
<0.001 
Albuminuria <30 mg/g creatinine 
and blood pressure <140/90 
mmHg (%) 
 
74.9 71.9 81.8 67.9 75.9 70.2 <0.001 
Systolic/diastolic blood pressure 
(mmHg)  in subjects with urinary 
albumin excretion <30 mg/g 
creatinine 
 
136 / 
79 
±17/10 
139 10 / 
81 3  
±18/9 
134 2 / 
78 11 
±15/9 
138 10 / 
78 8;11 
±17/10 
138 10 
/83 7;9 
±18/11 
135 / 
78 8;11 
±16/10 
<0.001 
Albuminuria >30 mg/g creatinine 
and blood pressure <130/80 
mmHg (%) 
14.9 15.4 17.5 8.3 19.8 12.6 <0.001 
 
Systolic/diastolic blood pressure 
(mmHg) in subjects with urinary 
albumin excretion ≥30 mg/g 
creatinine 
 
140 / 
81 
±18/11 
145 10 / 
84 7;9:10  
±20/10 
136 11 / 
78 8;11  
±17/10 
141 / 
79 8;11  
±20/11 
139 / 
84 7;9  
±17/12 
141 / 
80 8;11  
±19/13 
<0,001 
Blood pressure urinary albuminuria 
<30 versus ≥30 mg/g creatinine;  
p-value for systolic/diastolic blood 
pressure 
<0.001 / 
0.006 
0.001 / 
0.024 
0.009 / 
0.401 
0.042 / 
0.477 
0.363 / 
0.796 
0.005 / 
0.155 
 
1 significantly different from all countries  
2 significantly different from all countries except Scotland 
3 significantly different from all countries except Poland  
4 significantly different from all countries except the Netherlands 
5 significantly different from all countries except Hungary  
6 significantly different from all countries except Austria 
7 significantly different from Scotland 
8 significantly different from Poland 
9 significantly different from the Netherlands 
10 significantly different from Hungary 
11 significantly different from Austria 
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Table 5: Use of agents that block the renin-angiotensin system 
 total Austria Hungary Netherlands Poland Scotland p-value 
% of patients treated with ACE 
inhibitors/ARBs 
76.0 72.1 87.4 66.7 69.5 72.8 <0.001 
% of patients in any G but A1 stage treated 
with ACE inhibitors/ARBs 
74.1 69.1 86.9 65.2 67.2 68.6 <0.001 
% of patients in any G stage but A2 or A3 
stage treated with ACE inhibitors/ARBs 
84.6 81.3 94.9 75.7 73.9 88.3 <0.001 
any G and A1 versus any G and A2 or A3; p- 
value 
<0.001 0.004 <0.001 0.027 0.117 <0.001  
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Table 6: Serum cholesterol levels and use of statins according to guidelines and in specific 
subpopulations  
 total Austria Hungary Netherlands Poland Scotland 
p-value 
(countries) 
Serum total cholesterol 
[mg/dl] 
176  
(147;208) 
194 3 
(166; 
224) 
182 1 
(151;216) 
162 2 
(137;185) 
183 6 
(150; 224) 
166 4 
(143; 189) 
<0.001 
% of subjects > 40 years of 
age treated with statins 
60.5 46.3 62.8 66.1 39.8 82.7 <0.001 
% of subjects in stage G1 
or G2 and A1 treated with 
statins 
58.9 40.5 61.6 66.7 33.5 79.7 <0.001 
% of all other subjects 
treated with statins 
60.6 53.1 62.5 66.3 44.7 84.4 <0.001 
G1 or G2 and A1 vs. all 
others 
0.297 0.002 0.741 0.929 0.009 0.230  
Age (years)        
no statin therapy 61±11 63 4 ±10 61 1 ±11 64 6 ±9 57 2  ±11 56 3  ±13 <0.001 
statin therapy 64±9 65  ±9 65  ±9 65  ±8 63  ±9 61  ±8 <0.001 
p-value (statins yes/no) >0.001 0.013 <0.001 0.048 <0.001 <0.001  
Gender        
 male on statins (%) 61.8 46.2 61.3 68.7 40.9 61.8 <0.001 
 female on statins (%) 56.7 45.6 62.1 62.0 36.6 56.7 <0.001 
p-value (statins yes/no) >0.001 0.869 0.744 0.037 0.312 0.248  
Coronary artery disease        
no -  on statin therapy (%) 56.3 41.3 58.6 67.1 28.6 56.3 0.098 
yes -  on statin therapy (%) 73.3 65.5 73.1 74.8 64.4 73.3 <0.001 
p-value (statins yes/no)  >0.001 >0.001 >0.001 0.062 >0.001 >0.001  
Heart failure NYHA III/IV        
no -  on statin therapy (%) 40.1 45.3 61.1 n.a 37.6 80.6 0.053 
yes -  on statin therapy (%) 59.9 59.3 80.9 n.a 61.1 80.0 <0.001 
p-value (statins yes/no) 0.022 0.15 0.006 n.a 0.043 0.972  
Peripheral artery disease        
no -  on statin therapy (%) 59.4 44.6 61.0 68.6 37.3 59.4 0.011 
yes -  on statin therapy (%) 66.5 60.0 68.5 71.4 49.0 66.5 <0.001 
p-value (statins yes/no) 0.019 0.036 0.099 0.820 0.109 0.151  
Cerebrovascular disease        
no -  on statin therapy (%) 59.3 44.6 61.1 68.5 36.1 59.3 0.001 
yes -  on statin therapy (%) 67.6 57.1 68.8 77.8 61.2 67.6 <0.001 
p-value (statins yes/no) 0.009 0.058 0.110 0.552 0.001 0.080  
LDL cholestrol (mgdl)        
no statin therapy 
116 
(92.7; 140) 
128 3  
(107; 
153) 
109.7 2;4 
(86.5; 
133.8) 
100.4 2;5  
(77.2; 131.3) 
124.0 6 
(104.2; 
142.2) 
112 4;5  
(96.5; 
142.9) 
<0.0001 
statin therapy 
85.7  
(68; 110.4) 
97 7;9;10  
(78; 123) 
84.9 8;9;11 
(65.6; 
115.4) 
81.1 2  
(65.6; 100.4) 
104.1 9;10  
(77.2; 139) 
82.2 8;11 
(66.5; 99.4) 
<0.001 
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p-value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001  
1 significantly different from all countries  
2 significantly different from all countries except Scotland 
3 significantly different from all countries except Poland  
4 significantly different from all countries except the Netherlands 
5 significantly different from all countries except Hungary  
6 significantly different from all countries except Austria 
7 significantly different from Scotland 
8 significantly different from Poland 
9 significantly different from the Netherlands 
10 significantly different from Hungary 
11 significantly different from Austria 
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Table 7: Use of ASA according to guidelines and in specific subpopulations 
 Total Austria Hungary Netherlands Poland Scotland p-value 
(countries) 
% of subjects >50 years of age 
treated with ASA 
28.9 26.8 35.5 5.2 43.8 43.6 <0.001 
% of subjects in stage G1 or G2 
and A1 treated with ASA  
23.2 21.6 29.6 4.2 35.8 34.6 <0.001 
% of subjects all other subjects 
treated with ASA 
34.9 29.4 39.7 7.8 41.6 52.5 <0.001 
G1 or G2 and A1 vs. all others <0.001 0.028 <0.001 0.047 0.173 <0.001  
Age         
no ASA therapy 62.2 ± 
10.4 
63.4 7;8 ± 
9.9 
62.0 6 ± 
10.8 
64.9 6 ±  
8.8 
57.2 2 ± 
11.4 
58.9 3 ± 
9.9 
<0.001 
ASA therapy 64.8 ± 
8.5 
67.2 7;8 ± 
7.9 
65.6 7;8 ± 
8.3 
66.6 7 ±  
6.5 
63.1 7;10 ± 
8.7 
62.3 3 ± 
8.0 
<0.001 
p-value (ASA) <0.001 <0.001 <0.001 0.201 <0.001 <0.001  
Gender (ASA yes)        
 male on ASA therapy 28.9 26.3 36.4 5.2 43.6 28.9 <0.001 
 female on ASA therapy 25.1 23.0 30.6 4.4 34.7 25.1 <0.001 
p-value (ASA) 0.006 0.334 0.021 0.564 0.036 0.014  
Coronary artery disease        
no -  on ASA therapy 21.5 18.1 27.6 3.6 27.1 21.5 <0.001 
yes -  on ASA therapy 50.4 53.8 55.7 9.0 68.5 50.4 0.009 
p-value (ASA) <0.001 <0.001 <0.001 0.004 <0.001 <0.001  
Heart failure NYHA III/IV        
no -  on ASA therapy 52.6 24.5 32.7 na 37.6 27.0 0.003 
yes -  ASA 27.6 33.3 59.6 na 61.1 52.6 0.072 
p-value (ASA) <0.001 0.299 0.000 na 0.043 0.352  
Peripheral artery disease        
no -  on ASA therapy 26.1 23.1 32.0 4.6 36.7 26.1 <0.001 
yes -  on ASA therapy  47.5 46.0 50.4 7.1 55.1 47.5 <0.001 
p-value (ASA) <0.001 <0.001 <0.001 0.656 0.011 0.512  
Cerebrovascular disease        
no -  on ASA therapy  26.0 23.4 32.1 4.7 34.8 26.0 <0.001 
yes -  on ASA therapy  50.4 38.1 51.8 .0 73.5 50.4 0.002 
p-value (ASA) <0.001 0.011 <0.001 0.505 0.000 0.333  
1 significantly different from all countries  
2 significantly different from all countries except Scotland 
3 significantly different from all countries except Poland  
4 significantly different from all countries except the Netherlands 
5 significantly different from all countries except Hungary  
6 significantly different from all countries except Austria 
7 significantly different from Scotland 
8 significantly different from Poland 
9 significantly different from the Netherlands 
10 significantly different from Hungary 
11 significantly different from Austria 
